Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENOBNASDAQ:HEPANASDAQ:LPTXNASDAQ:ORGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOBEnochian Biosciences$0.61$0.39▼$2.99$40.80M1.09137,347 shs88,300 shsHEPAHepion Pharmaceuticals$0.07-7.3%$0.34$0.07▼$68.00$779K1.91.30 million shs62,452 shsLPTXLeap Therapeutics$0.38+4.5%$0.36$0.22▼$4.79$15.79M-0.17832,245 shs220,702 shsORGSOrgenesis$2.00+5.3%$2.30$0.87▼$10.80$9.60M0.729,590 shs2,454 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOBEnochian Biosciences0.00%0.00%0.00%0.00%0.00%HEPAHepion Pharmaceuticals-7.31%-12.35%-75.30%-99.09%-99.87%LPTXLeap Therapeutics+4.50%+0.26%-4.73%-20.66%-83.99%ORGSOrgenesis+5.26%-0.50%-13.61%-47.64%+199,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOBEnochian BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals0.335 of 5 stars0.05.00.00.00.00.00.6LPTXLeap Therapeutics2.5206 of 5 stars3.14.00.00.03.30.01.3ORGSOrgenesisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOBEnochian Biosciences 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/ALPTXLeap Therapeutics 2.25Hold$4.921,190.46% UpsideORGSOrgenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LPTX, ORGS, HEPA, and ENOB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOBEnochian BiosciencesN/AN/AN/AN/A$1.37 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/AORGSOrgenesis$662K14.50N/AN/A($6.58) per share-0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOBEnochian Biosciences-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/AHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)LPTXLeap Therapeutics-$81.41M-$1.70N/AN/AN/AN/A-116.24%-93.18%8/11/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)Latest LPTX, ORGS, HEPA, and ENOB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOBEnochian BiosciencesN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOBEnochian BiosciencesN/A0.330.33HEPAHepion PharmaceuticalsN/A1.301.30LPTXLeap TherapeuticsN/A3.973.97ORGSOrgenesisN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOBEnochian Biosciences7.16%HEPAHepion Pharmaceuticals17.24%LPTXLeap Therapeutics30.46%ORGSOrgenesis22.56%Insider OwnershipCompanyInsider OwnershipENOBEnochian Biosciences21.72%HEPAHepion Pharmaceuticals4.70%LPTXLeap Therapeutics5.40%ORGSOrgenesis5.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOBEnochian Biosciences2258.28 million45.63 millionNot OptionableHEPAHepion Pharmaceuticals2010.98 million6.63 millionNo DataLPTXLeap Therapeutics4041.44 million36.25 millionOptionableORGSOrgenesis1504.80 million4.53 millionNo DataLPTX, ORGS, HEPA, and ENOB HeadlinesRecent News About These CompaniesOrgenesis (NASDAQ:ORGS) Shares Down 5.5% - Time to Sell?May 24, 2025 | americanbankingnews.comOrgenesis Delays Filing of Quarterly ReportMay 16, 2025 | tipranks.comOrgenesis Delays 10-K Filing Amid Financial ChallengesApril 1, 2025 | tipranks.comOrgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury TherapiesMarch 6, 2025 | accessnewswire.comOrgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comOrgenesis secures $5M equity investment from Williamsburg VentureJanuary 29, 2025 | markets.businessinsider.comOrgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | finanznachrichten.deOrgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | accessnewswire.comOrgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comOrgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comIs Orgenesis Stock (ORGS) a Good Investment?September 19, 2024 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, ORGS, HEPA, and ENOB Company DescriptionsEnochian Biosciences NASDAQ:ENOBEnochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.07 -0.01 (-7.31%) As of 05/27/2025 03:39 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Leap Therapeutics NASDAQ:LPTX$0.38 +0.02 (+4.50%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Orgenesis NASDAQ:ORGS$2.00 +0.10 (+5.26%) As of 05/27/2025 03:43 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
